Abstract: The present invention includes compositions and methods that utilize a Universal Immune Receptor (UnivIR) CAR system comprising a modified T cell comprising a DOTA CAR and a DOTA-conjugated targeting ligand. In certain embodiments, the invention includes methods for treating, ameliorating, and/or preventing cancer. In certain embodiments, the invention provides a set of complementary molecular imaging tools that is applicable to CAR T cell therapy.

Abstract: A computer-implemented method includes refreshing a set of memory channels in a memory system substantially simultaneously, each memory channel refreshing a rank that is distinct from each of the other ranks being refreshed. Further, the method includes marking a memory channel from the set of memory channels as being unavailable for the rank being refreshed in the memory channel. In one or more examples, the method further includes blocking a fetch command to the memory channel for the rank being refreshed in the memory channel.

Abstract: A method for providing secure single sign on includes receiving a first data object from an application hosting server, the first data object indicating at least a service provider name and identifying a configuration file corresponding to the service provider name, wherein the configuration file includes at least trusted identity information. The method also includes determining, using the configuration file corresponding to the service provider name, whether the first data object is valid and, in response to a determination that the first data object is valid, generating a response message.

Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.

Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.

Abstract: Supercooled water or solutions can be destabilized by the nucleation of ice, which can be triggered by a wide range of different mechanisms. Constraining water in a constant-volume (isochoric) container minimizes the effects of many of these mechanisms through thermodynamic, kinetic, and fluid dynamic means, significantly enhancing supercooling stability. This invention describes methods and devices for high-stability and optionally transportable supercooling of aqueous solutions or suspensions, and the stable and long-term preservation of biological matter that may be stored therein.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: The invention provides a kit for detecting the presence or absence of mutations in the selected regions of the target genes associated with colorectal cancer, comprising XNA clamps and primers; wherein the XNA clamps are capable of hybridizing with the selected regions having wild-type sequences in the target genes, and the primers are capable of amplifying the selected regions containing each of the mutations in the target genes. The invention also discloses a method of detecting a mutant gene associated with colorectal cancer, comprising: providing a sample containing DNA and a xeno nucleic acid clamp capable of hybridizing to a wild-type gene; and detecting a mutant of the gene in the sample with a xeno nucleic acid probe capable of hybridizing to the mutant gene.

Abstract: The disclosed tamper-evident closure (100) encloses a medical access device, such as a vascular access device (200), such that it will be visibly apparent if the medical access device contained in the tamper-evident closure becomes exposed. The tamper-evident closure cannot be reapplied over the medical access device in a way to look the same as it did prior to exposing the medical access device. The tamper-evident closures comprise a holding cavity (110), a securing mechanism (160), and an apparent release. The disclosed tamper-evident closures are well suited for securing a medical access device that has an access point for delivering fluid to a patient or removing fluid from a patient.

Abstract: An integrally formed bucket and external organizer is provided. A bucket is provided having a tubular sidewall with an open upper end and a closed bottom end. An integrally formed brim connects to an outside surface of the tubular sidewall proximate to the open upper end. The brim extends radially outward from the tubular sidewall to an external or exterior edge. The brim includes a plurality of apertures that extend though its surface (e.g., between an interior edge attached to the tubular sidewall and the exterior edge). Such apertures may support various items (e.g., tools, fishing gear, etc.).

Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for Mullerian inhibiting substance type 2 receptor (MISIIR). Compositions and methods of treatment of ovarian and other gynecologic cancers are also provided.

Abstract: One or more memory systems, architectural structures, and/or methods of storing information in memory devices is disclosed to improve the data bandwidth and or to reduce the load on the communications links in a memory system. The system may include one or more memory devices, one or more memory control circuits and one or more data buffer circuits. In one embodiment, the Host only transmits data over its communications link with the data buffer circuit. In one aspect, the memory control circuit does not send a control signal to the data buffer circuits. In one aspect, the memory control circuit and the data buffer circuits each maintain a separate state machine-driven address pointer or local address sequencer, which contains the same tags in the same sequence. In another aspect, a resynchronization method is disclosed.

Abstract: A memory controller receives, via a first interface, a first read request requesting a requested data granule. Based on receipt of the first read request, the memory controller transmits, via a second interface, a second read request to initiate access of the requested data granule from a system memory. Based on a determination to schedule accelerated data delivery and receipt by the memory controller of a data scheduling indication that indicates a timing of future delivery of the requested data granule, the memory controller requests, prior to receipt of the requested data granule, permission to transmit the requested data granule on the system interconnect fabric. Based on receipt of the requested data granule at the indicated timing and a grant of the permission to transmit, the memory controller initiates transmission of the requested data granule on the system interconnect fabric and transmits an error indication for the requested data granule.

Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.

Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.

Abstract: The present invention relates to methods of increasing proliferation and/or programming differentiation status of T cells comprising genetically modifying the cells to inducibly express FOXO1-3A or TCF7 when activated. Also provided are engineered cells modified to inducibly express FOXO1-3A or TCF7 when activated; and methods of treating disease using the engineered cells. Also provided are methods of screening and identifying receptors that specifically bind an antigen or antigens that specifically bind a receptor.

Abstract: The use of genes or biomarkers to more accurately diagnose aggressive prostate cancer in men of African descent or European descent is provided. More specifically, the genes or biomarkers of the present invention can be used in diagnostic tests and methods to determine, qualify, and/or assess aggressive prostate cancer or status, for example, to diagnose or identify aggressive prostate cancer, in an individual, subject, or patient, such as men of African descent or men of European descent.

Abstract: A speaker system uses multiple sound chambers having phi ratios to create a dampening effect to filter out incoherent sounds, thus creating an enhanced listening experience that feels very natural to the listener. The speaker system has at least a sound driver, a first sound chamber having a first volume, and a second sound chamber having a second volume that is approximately 1.6 times the first volume. The speaker system can also have a second sound driver, and a third sound chamber having a third volume that is that is approximately 1.6 times the second volume.

Abstract: Multilayer films comprise polypeptide epitopes from Plasmodium falciparum, specifically a circumsporozoite CIS43 epitope and one or more of circumsporozoite T1, B or T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a Plasmodium protozoan.